Cargando…

Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

OBJECTIVES: To describe the long‐term effects of ivacaftor (Kalydeco®) in individuals with cystic fibrosis (CF) on body mass index (BMI), body composition (BC), pulmonary function (PF), resting energy expenditure (REE), and exercise capacity (EC) after ≥12 months of treatment. WORKING HYPOTHESIS: BM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burghard, M (Marcella), Berkers, G (Gitte), Ghijsen, S (Sophie), Hollander‐Kraaijeveld, FM (Francis), de Winter‐de Groot, KM (Karin), van der Ent, CK (Kors), Heijerman, HGM (Harry), Takken, T (Tim), Hulzebos, HJ (Erik)
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317816/ https://www.ncbi.nlm.nih.gov/pubmed/32233113 http://dx.doi.org/10.1002/ppul.24745

Ejemplares similares

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
por: Kristensen, Maartje I., et al.
Publicado: (2021)

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients
por: Gostelie, Romee, et al.
Publicado: (2020)

Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation
por: Burghard, Marcella, et al.
Publicado: (2022)

Nonpulmonary Outcomes of Asbestos Exposure
por: Bunderson-Schelvan, Melisa, et al.
Publicado: (2011)

Risk of nonpulmonary infections requiring hospitalization in spondyloarthritis
por: Chung, Ho Yin, et al.
Publicado: (2022)

Management consideration in nonpulmonary visceral metastatic seminoma of testis.
por: Park, D. S., et al.
Publicado: (1999)

Pulmonary versus Nonpulmonary Nontuberculous Mycobacteria, Ontario, Canada
por: Brode, Sarah K., et al.
Publicado: (2017)

Pulmonary Nodules in Patients With Nonpulmonary Cancer: Not Always Metastases
por: Caparica, Rafael, et al.
Publicado: (2016)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

Survey of acute exacerbation after nonpulmonary surgery in patients with interstitial pneumonia
por: Hamada, Miho, et al.
Publicado: (2021)

Role of international normalized ratio in nonpulmonary sepsis screening: An observational study
por: Zhang, Jing, et al.
Publicado: (2021)

1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
por: Milgrom, Alexander, et al.
Publicado: (2019)

Nonpulmonary risk factors of acute respiratory distress syndrome in patients with septic bacteraemia
por: Nam, Hyunseung, et al.
Publicado: (2019)

CT Scans Obtained for Nonpulmonary Indications: Associated Respiratory Findings of COVID-19
por: Hossain, Rydhwana, et al.
Publicado: (2020)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

1251. Strengthening Antimicrobial Stewardship Programs through Public Health Support
por: Kriengkauykiat, Jane, et al.
Publicado: (2023)

A new interpretation of nonpulmonary vein substrates of the left atrium in patients with atrial fibrillation
por: Rillo, Mariano, et al.
Publicado: (2021)

Impact of COVID-19 on Nonpulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes
por: Pirzadeh, Mina, et al.
Publicado: (2023)

A Descriptive Analysis of 1251 Solid Organ Transplant Visits to the Emergency Department
por: Unterman, Sarah, et al.
Publicado: (2009)

Strategies for repeat ablation for atrial fibrillation: A multicentre comparison of nonpulmonary vein versus pulmonary vein target ablation
por: Mol, Daniel, et al.
Publicado: (2022)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

P1251: BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION
por: Ceccato, J., et al.
Publicado: (2022)

The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol
por: Terpstra, L.C., et al.
Publicado: (2022)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Measured transverse‐axis dosimetric parameters of the model STM1251 [Formula: see text] interstitial source
por: Li, Z., et al.
Publicado: (2002)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Effect of Gonadotropin Types and Indications on Homologous Intrauterine Insemination Success: A Study from 1251 Cycles and a Review of the Literature
por: Cabry-Goubet, Rosalie, et al.
Publicado: (2017)

Circulating Th1 and Th2 Subset Accumulation Kinetics in Septic Patients with Distinct Infection Sites: Pulmonary versus Nonpulmonary
por: Xue, Ming, et al.
Publicado: (2020)

1251. Contaminated Sinks May be an Environmental Source for Serial Transmission of Carbapenem-Resistant Enterobacteriaceae (CRE) to ICU Patients
por: Lewis, Sarah S, et al.
Publicado: (2018)

Bridging for lung transplantation with lumacaftor/ivacaftor
por: Pedersen, Søren Sperling, et al.
Publicado: (2018)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report
por: Welsner, Matthias, et al.
Publicado: (2019)

Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
por: Schneider, Elena K.
Publicado: (2018)

2017 Dutch Report Card(+): Results From the First Physical Activity Report Card Plus for Dutch Youth With a Chronic Disease or Disability
por: Burghard, Marcella, et al.
Publicado: (2018)

Ivacaftor Therapy in CF Patients: Single Center Experience
por: Mondal, Pritish, et al.
Publicado: (2014)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Pain During a Marathon Run: Prevalence and Correlates in a Cross-Sectional Study of 1,251 Recreational Runners in 251 Marathons
por: O'Connor, Patrick J.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3re861gbfvr8jsgdkg5cjsq38b